Compare UDMY & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UDMY | ZVRA |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 716.5M | 653.2M |
| IPO Year | 2021 | 2015 |
| Metric | UDMY | ZVRA |
|---|---|---|
| Price | $4.63 | $10.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $9.29 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 105.36 | ★ 159.21 |
| EPS | N/A | ★ 0.60 |
| Revenue | ★ $789,844,000.00 | $106,470,000.00 |
| Revenue This Year | $4.12 | $37.27 |
| Revenue Next Year | $4.54 | $53.42 |
| P/E Ratio | ★ N/A | $17.05 |
| Revenue Growth | 0.42 | ★ 350.91 |
| 52 Week Low | $4.02 | $7.16 |
| 52 Week High | $8.09 | $13.16 |
| Indicator | UDMY | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.24 | 48.99 |
| Support Level | $4.23 | $8.30 |
| Resistance Level | $5.20 | $11.07 |
| Average True Range (ATR) | 0.30 | 0.62 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 46.77 | 18.05 |
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Enterprise segment and Consumer segment, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America, and also has its presence in Europe, Middle East, Africa; Asia Pacific; and Latin America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.